Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.74 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 5/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30302143 | 0.88 | TRPV6 (0.69) | TRPV6CHRNB2CHRNA4TDP1LMNA | |
| SCHEMBL20567623 | 0.88 | TRPV6 (0.69) | TRPV6CHRNB2CHRNA4TDP1LMNA | |
| SCHEMBL20570424 | 0.84 | TRPV6 (0.70) | TRPV6LMNAKDM4EALDH1A1HTT | |
| SCHEMBL6499571 | 0.82 | ALDH1A1 (0.75) | TRPV6TDP1LMNAKDM4EALDH1A1 | |
| SCHEMBL6496864 | 0.81 | ALDH1A1 (0.73) | TRPV6TDP1LMNAKDM4EALDH1A1 | |
| SCHEMBL19206082 | 0.80 | ALDH1A1 (0.58) | TRPV6TDP1LMNAKDM4EALDH1A1 | |
| SCHEMBL20567182 | 0.79 | TRPV6 (0.59) | TRPV6LMNAKDM4EALDH1A1FAAH | |
| N-(3-Pyridylmethyl)Pyrrolidine SCHEMBL30341021 | 0.78 | CHRNB2 (1.00) | TRPV6CHRNB2CHRNA4TDP1KDM4E | |
| N-(3-Pyridylmethyl)Pyrrolidine SCHEMBL1538320 | 0.78 | CHRNB2 (1.00) | TRPV6CHRNB2CHRNA4TDP1KDM4E | |
| SCHEMBL3763705 | 0.78 | ALDH1A1 (0.57) | TRPV6TDP1LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | TRPV6 9/4885CHRNB2 650/4885CHRNA4 395/4885 |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | CACNA1B, CACNG6, SCN5A | TRPV6 9/4885CHRNB2 650/4885CHRNA4 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.